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ABSTRACT
The fungus Paecilomyces lilacinus is an emerging pathogen that causes severe human infections, including
devastating oculomycosis. Usually, it shows low susceptibility to conventional antifungal drugs in vitro,
and variable susceptibility to novel triazoles. A review of the published literature identiﬁed 119 reported
cases of human infection by P. lilacinus between 1964 and 2004. Most were cases of oculomycosis (51.3%),
followed by cutaneous and sub-cutaneous infections (35.3%), and a smaller group of miscellaneous
infections (13.4%). Lens implantation is the most frequent predisposing factor for oculomycosis.
Cutaneous and sub-cutaneous infections occur mainly in solid organ and bone marrow transplant
recipients, although surgery and primary or acquired immunodeﬁciency are also relevant predisposing
factors. Infections in apparently immunocompetent patients have also been reported. Surgical debride-
ment combined with antifungal drug therapy, or the correction of predisposing factors, such as
neutropenia, are usually required to obtain improvement. Treatment with traditional antifungal drugs
often fails. Voriconazole has demonstrated good activity in both cutaneous and ocular infections in the few
cases in which this drug has been used. The new triazoles ravuconazole and posaconazole show good in-
vitro activity against P. lilacinus and could be promising therapeutic alternatives.
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INTRODUCTION
Fungal infections have become an important
cause of morbidity and mortality in recent years,
especially in the ever-expanding population of
immunocompromised patients. Antibacterial
treatment, bone marrow and solid organ
transplantation, oncological chemotherapy, and
primary or acquired immunodeﬁciency are all
predisposing circumstances for the development
of severe fungal infection [1]. In addition to the
traditional and well-known opportunistic fungi,
such as Candida, Aspergillus and Cryptococcus,
many other fungi have now emerged as causes
of human infection. Paecilomyces is among the
latter, and is of clinical interest because of its
pathogenicity and resistance to antifungal agents.
Paecilomyces is a hyaline hyphomycete that
exists worldwide. It can be recovered from soil
and air, and can cause the deterioration of grain,
food and paper [2]. Its potential resistance to
sterilising methods, its frequent contamination of
creams and lotions used clinically, and its coloni-
sation of clinical materials, e.g., catheters and
plastic implants, increases the clinical importance
of this fungus [3,4]. Although Paecilomyces spp.
are uncommon pathogens, they can produce
serious infections in immunocompromised pa-
tients, and the incidence of infections in immu-
nocompetent hosts is increasing [5]. Paecilomyces
lilacinus and Paecilomyces variotii are the two
species associated most frequently with human
disease. Other species reported to infect humans
occasionally are Paecilomyces marquandii [6,7] and
Paecilomyces javanicus [8]. This article reviews
cases of P. lilacinus infection reported between
1964 and 2004, and summarises the available data
concerning the main clinical manifestations, pre-
disposing factors, treatments and outcome. Data
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concerning the in-vitro susceptibility of this fun-
gus are also reviewed.
CLINICAL RELEVANCE OF
P. LILACINUS
Despite its apparently moderate virulence [9],
P. lilacinus is able to infect both immunocom-
promised and immunocompetent hosts [2]. The
portal of entry of the fungus usually involves
breakdown of the skin barrier, indwelling cath-
eters or inhalation. On some occasions, ﬂuids
contaminated by P. lilacinus have caused infec-
tions of eye structures [10,11] or the skin [12].
The ability to sporulate in tissue and to produce
numerous conidia could explain the tendency of
this species for dissemination in the human
body [13]. Most clinical manifestations corres-
pond to oculomycosis and cutaneous and sub-
cutaneous infections, although other types of
infection have also been reported less com-
monly.
Ocular infections
P. lilacinus shows a special tropism for ocular
structures. Table 1 summarises the 23 reports of
oculomycosis caused by P. lilacinus, involving 55
patients, published between 1964 and 2004. Also
included in Table 1 are ﬁve new cases from
Brazil that were recently conﬁrmed in our
laboratory. Although details of these cases are
incomplete, they are included in order to
emphasise the wide distribution of this patho-
gen, as its involvement in ocular infection had
not been reported previously in Brazil. Ocul-
omycosis caused by P. lilacinus seems to occur
worldwide, but interestingly, nine of the 60
cases reported were from Australia [14–19]. The
age of patients was 20—92 years, and no signi-
ﬁcant gender differences were noticed. Keratitis
and endophthalmitis were the most common
clinical manifestations. The most common pre-
disposing factors were intra-ocular lens implan-
tation (32.8%), non-surgical trauma with or
without a foreign body (20%), ophthalmic sur-
gery (10%), and the wearing of contact lenses
(3.3%). Signiﬁcantly, in most cases, patients
received topical and ⁄ or systemic costicosteroid
treatment at the start of infection. In some cases,
no predisposing factors were identiﬁed [13,18].
Mortality has never been associated with pri-
mary oculomycosis caused by P. lilacinus, but
enucleation of the affected eye (38%) and loss of
vision (25%) were the outcome of the infection
in many cases.
In practically all cases of oculomycosis report-
ed (57 ⁄ 60), P. lilacinus was isolated from the
lesions. In two cases, the aetiology of the
infection was established only through histolog-
ical studies and was not conﬁrmed by culture
[16,20], and in one case the isolate was not
identiﬁed to the species level [16]. However,
these three cases were attributed erroneously to
P. lilacinus in retrospective reviews [21,22]. A
case in which the aetiological agent was Paeci-
lomyces viridis [23] was also attributed errone-
ously to P. lilacinus [21,22,24,25].
Cutaneous and sub-cutaneous infections
Details of 42 patients with cutaneous and sub-
cutaneous P. liacinus infections between 1977 and
2004 are summarised in Table 2. The majority
(50%) of these infections were reported from the
USA, although cases from other countries, e.g.,
Australia, Brazil, France, Germany, Iceland,
Japan, Korea, Spain, Switzerland and the UK,
have also been reported. Patient age ranged from
4 to 86 years and there were no signiﬁcant
gender differences. The most common predispo-
sing factors were solid organ (27.9%) and bone
marrow transplantation (11.6%), corticosteroid
therapy (9.3%), malignancies (20.9%), primary
immunodeﬁciency (2.4%), AIDS (2.4%), diabetes
mellitus (2.4%) and hepatic cirrhosis (2.4%).
In eight cases (18.6%), predisposing factors
for infection were unknown or not reported
[4,26–31].
Cutaneous infections are usually sporadic, but
an outbreak affecting nine immunocompromised
patients in a bone marrow transplant unit, related
to the common use of a skin lotion, was described
in Switzerland [12,32]. The outbreak lasted for a
period of 3 months, and affected ﬁve patients
following allogeneic bone marrow transplantation
and four patients with aplasia after chemotherapy
for haematological malignancies; two of the
patients died.
Cutaneous and sub-cutaneous infections usu-
ally appear insidiously and can manifest with a
wide range of clinical features. They consist of
solitary or disseminated skin eruptions with
erythematous macules, papules, vesicles or
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Table 1. Reported cases of oculomycosis caused by Paecilomyces lilacinus
Case Year Reference Country
Age ⁄
gender Infection Predisposing factors Treatment Outcome
1 1964 [81] USA 81 ⁄ F Keratitis Ocular surgery
(cataract extraction)
Surgery, topical
and systemic AMB
Recovery
2 1973 [93] Argentina 41 ⁄M Endophthalmitis Ocular surgery
(iridenclisis)
Sub-conjunctival ⁄ intra-vitreal
AMB
Loss of vision
3 1977 [10] USA 61 ⁄M Endophthalmitis Lens implantation Surgery Eye enucleation
4–15 1977 [77] USA NR Endophthalmitis Lens implantation AMB, 5FC Eye enucleation in six cases,
loss of vision in six cases
16 1978 [78] USA 76 ⁄M Endophthalmitis Lens implantation Surgery, 5FC, intra-ocular
and systemic AMB,
intra-ocular 5FC and MCZ,
topical and oral TBZ
Recovery
17 1980 [20] USA 61 ⁄M Endophthalmitis Lens implantation Surgery Eye enucleation
18 1980 USA 70 ⁄M Endophthalmitis Lens implantation Local and oral 5FC Loss of vision
19 1980 USA 72 ⁄M Endophthalmitis Lens implantation Surgery Eye enucleation
20 1980 USA 92 ⁄ F Endophthalmitis Lens implantation Local AMB Eye enucleation
21 1980 USA 84 ⁄ F Endophthalmitis Lens implantation Topical AMB eye enucleation
22 1980 USA 70 ⁄ F Endophthalmitis Lens implantation Sub-conjuntival ⁄ intra-ocular
AMB, 5FC
Loss of vision
23 1980 USA 81 ⁄ F Endophthalmitis Lens implantation Surgery Eye enucleation
24 1980 USA 79 ⁄M Endophthalmitisa Lens implantation Antibioticsb Loss of vision
25 1980 USA 89 ⁄M Endophthalmitis Lens implantation Intra-ocular AMB, 5FC Eye enucleation
26 1980 USA 76 ⁄M Endophthalmitis Lens implantation Intra-vitreal AMB Eye enucleation
27 1980 USA 76 ⁄ F Endophthalmitisa Lens implantation Topical AMB, 5FC Recovery
28 1980 USA 72 ⁄ F Endophthalmitis Lens implantation AMB Eye enucleation
29 1984 [24] USA 70 ⁄M Keratitis Lens implantation Surgery, intra-ocular
AMB and MCZ,
intra-ocular MCZ, 5FC
Eye enucleation
30 1984 USA 72 ⁄ F Keratitis Herpes zoster Surgery, intrao-cular MCZ,
5FC, MCZ
Eye enucleation
31 1984 USA 76 ⁄ F Keratitis Local corticosteroids Surgery, topical MCZ Recovery
32 1985 [65] USA 76 ⁄ F Keratitis Corneal transplant Topical pimaricin, MCZ
and AMB, systemic MCZ,
second corneal transplant
Recovery
33 1987 [82] USA 79 ⁄M Endophthalmitis Lens implantation Surgery, intra-vitreal AMB
and MCZ, MCZ, KTZ
Recovery
34 1987 [94] USA 76 ⁄ F Keratitis Contact lens Topical AMB, NTM,
surgery, topical MCZ
Recovery
35 1987 USA 71 ⁄ F Keratitis Contact lens Topical and
subconjunctival MCZ,
topical AMB, topical
KCZ, surgery
Recovery
36 1989 [14] Australia 43 ⁄NR Endophthalmitis Trauma ⁄ keratoplasty Topical NTM and MCZ,
surgery, intra-vitreal AMB,
MCZ and 5FC, systemic
AMB, intra-vitreal AMB
Recovery
37 1991 [15] Australia 20 ⁄M Endophthalmitis Minor trauma Systemic AMB Recovery
38 1992 [16] Australia 21 ⁄M Keratitis Eye sore ⁄dexametasone Topical and systemic
AMB, corneal transplant,
Intra-ocular AMB, ITZ,
surgery
Loss of vision
39‡ 1992 Australia 72 ⁄ F Keratitis Topical prednisolone Topical and systemic
AMB, surgery, surgery,
intra-vitreal and systemic
AMB
Loss of vision
40 1994 [79] France 65 ⁄ F Endophthalmitis Corneal ulceration Topical NTM, KCZ,
surgery, intra-vitreal AMB
Recovery
41 1994 [95] Japan 84 ⁄ F Endophthalmitis Ocular surgery Surgery, ECZ, MCZ Loss of vision
42 1996 [13] USA NR Keratitis Unknown NR NR
43 1996 USA NR Keratitis Unknown NR NR
44 1996 [12] Switzerland 48 ⁄M Endophthalmitis Chronic myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF, G-CSF,
GM-CSF
Death
45 1997 [21] UK 34 ⁄M Endophthalmitis ⁄
keratitis
Corticosteroid therapy Surgery, antibacterials,
intra-vitreal AMB, KCZ,
FCZ, ITZ, topical ECZ,
intra-ocular MCZ, KCZ
Recovery
46 2001 [17] Australia 30 ⁄M Endophthalmitis Corneal trauma Intra-ocular AMB, ITZ,
topical NTM and FCZ,
intra-ocular FCZ and AMB
Recovery
47 2001 [25] Spain 62 ⁄M Endophthalmitis Corneal ⁄ crystalline
trauma
Surgery, intra-vitreal and
systemic AMB, ITZ
Eye enucleation
48 2001 [80] USA 37 ⁄M Endophthalmitis Lens implantation Surgery, intra-ocular AMB Eye enucleation
49 2001 USA 68 ⁄ F Endophthalmitis Corneal ulceration Surgery, topical and
intra-ocular AMB,
FCZ, topical, sub-conjunctival
and intra-vitreal MCZ
Recovery
50 2001 USA 48 ⁄ F Endophthalmitis Corneal ulceration Surgery, intra-vitreal FCZ Recovery
51 2001 USA 23 ⁄M Endophthalmitis Lens implantation Surgery, intra-vitreal AMB,
intra-vitreal MCZ
Eye enucleation
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nodules with a necrotic centre [12,32]. Some cases
of soft-tissue infections, e.g., cellulitis, have also
been described [3,29,33–35].
Six (14.3%) of the 42 reported patients with
cutaneous infection caused by P. lilacinus died.
Although it is probable that the fungal infection
contributed to the fatal outcome, this was not
proven in all cases. Two patients suffered severe
graft vs. host disease after bone marrow trans-
plant, including one patient in whom the infection
disseminated [12,32]. In two other cases, the cause
of death was pneumonia, probably unrelated to
the infection [36], and multiple organ failure with
no documented dissemination of the infection
[28]. In two cases, the cause of death was not
described [13].
Non-ocular, non-cutaneous infections
Sixteen cases of non-ocular, non-cutaneous infec-
tions caused by P. lilacinus were described
between 1972 and 2003 (Table 3), seven of which
were from the USA. In ﬁve cases, no predisposing
factors were identiﬁed. The patients’ ages ranged
from 18 months to 57 years, and no differences
existed between genders. These infections in-
volved onychomycosis [37], vaginitis [5], lung
abscess [38], pleural effusion [39], sinusitis [40–
43], osteomyelitis [44], disseminated infection
[13,45] and fungaemia [46–49]. Sinusitis was the
most frequent type of non-cutaneous, non-ocular
infection (31.3%), followed by fungaemia (25%).
The cases of fungaemia were related to indwelling
central venous catheters. All of these cases were
resolved successfully following medical and sur-
gical treatment.
Diagnosis
As with most fungal infections, diagnosis of P.
lilacinus infection is based on culture of the fungus
and histology of the lesions. The fungus grows
well in routine media used for fungal culture. For
example, it grows rapidly on malt extract 2% w ⁄ v
agar, developing ﬂocculant vinaceous to violet
colonies [2], while it produces brownish colonies
on Sabouraud dextrose agar [50]. The vinaceous
pigmentation of the colonies and a careful study
of the microscopical features are the most useful
criteria for distinguishing this fungus from com-
mon contaminants, e.g., Penicillium, which shows
a similar arrangement of the fertile hyphae, or
from other more common pathogenic fungi, e.g.,
Aspergillus and Candida spp.
A peculiar characteristic of P. lilacinus men-
tioned above, i.e., its ability to sporulate in
infected tissue, can also be helpful in the diagno-
sis of these infections. This type of sporulation,
called ‘adventitious’ sporulation, involves the
production of reproductive structures similar to
those observed in vitro, i.e., phialides and conidia
[13]. Although deﬁnitive identiﬁcation of this
fungus requires culture, it can often be identiﬁed
provisionally in histological sections using rout-
ine stains that allow such structures to be
observed. Correct diagnosis of P. lilacinus is
important because of its intrinsic resistance to
conventional antifungal drugs.
Table 1. Reported cases of oculomycosis caused by Paecilomyces lilacinus
Case Year Reference Country
Age ⁄
gender Infection Predisposing factors Treatment Outcome
52 2002 [22] Switzerland 61 ⁄ F Endophthalmitis Lens implantation Surgery, FCZ, ITZ,
intra-ocular FCZ, VCZ
Recovery
53 2003 [18] Australia 69 ⁄M Endophthalmitis Unknown Surgery, intra-cameral
AMB, VCZ
Loss of vision
54 2003 Australia 44 ⁄M Endophthalmitis Unknown Surgery, AMB,
intra-vitreal AMB, VCZ
Recovery
55 2003 Australia 23 ⁄M Endophthalmitis Corneal foreign body Topical NTM and AMB,
ITZ, voriconazole
Recovery
56 2004 [19] Australia 61 ⁄M Keratitis Intra-corneal hair Surgery, topical NTM,
FCZ, VCZ plus TBF
Recovery
57 2004 PR Brazil 69 ⁄M Keratitis Retro-orbital lymphoma NR NR
58 2004 Brazil 28 ⁄M Keratitis Surgery AMB NR
59 2004 Brazil 63 ⁄M Keratitis Surgery NTM NR
60 2004 Brazil 28 ⁄ F Keratitis NR NR NR
61 2004 Brazil 32 ⁄ F Keratitis Corneal ulceration NR NR
aP. lilacinus infection not conﬁrmed; bnot speciﬁed; cPaecilomyces spp. not identiﬁed.
NR, not reported; PR, present report.
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
AMB, amphotericin B; ECZ, econazole; FCZ, ﬂuconazole; ITZ, itraconazole; KCZ, ketoconazole; MCZ, miconazole; NTM, natamycin; TBZ, thiobendazole; TBF, terbinaﬁne;
VCZ, voriconazole; 5FC, ﬂucytosine.
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Table 2. Reported cases of cutaneous and sub-cutaneous infections caused by Paecilomyces lilacinus
Case Year Reference Country Age ⁄ gender Infection Predisposing factors Treatment Outcome
1 1977 [85] Japan 28 ⁄ F Cutaneous Renal transplant AMB Chronic course
2 1977 [26] Japan 20 ⁄ F Cutaneous Unknown Topical CTZ, GSV Partial recovery
3 1979 [6] USA 56 ⁄ F Sub-cutaneous Renal transplant MCZ Recovery
4 1984 [27] Korea 19 ⁄M Cutaneous Unknown GSV, KTZ Recovery
5 1985 [83] USA 55 ⁄ F Sub-cutaneous Renal transplant Surgery Recovery
6 1986 [33] USA 47 ⁄M Sub-cutaneous Chronic lymphocytic
leukaemia
AMB, AMB plus 5FC Recovery
7 1986 [90] Italy 80 ⁄M Cutaneous Diabetes mellitus KTZ Recovery
8 1990 [69] Brazil 46 ⁄ F Cutaneous Renal transplant GSV Died
9 1990 [36] USA 6 ⁄ F Cutaneous Biphenotypic leukaemia AMB, AMB plus 5FC Died
10 1992 [87] USA 4 ⁄M Sub-cutaneous Chronic granulomatous
disease
AMB Recovery, died from
other causes
11 1996 [91] USA 55 ⁄M Cutaneous Lymphocytic lymphoma GSV, KTZ Recovery
12 1996 [9] USA 45 ⁄M Cutaneous Renal transplant Surgery Persistent infection,
recurrences
13 1996 USA 59 ⁄NR Sub-cutaneous Heart transplant Surgery, KTZ Persistent asymptomatic
nodules
14 1996 [12] Switzerland 50 ⁄M Cutaneous Chronic myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF
Recoverya
15 1996 Switzerland 14 ⁄ F Cutaneous Acute myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF
Died
16 1996 Switzerland 48 ⁄M Cutaneous Chronic myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF, G-CSF,
GM-CSF
Died
17 1996 Switzerland 50 ⁄M Cutaneous Acute myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF
Recovery
18 1996 Switzerland 47 ⁄M Cutaneous Chronic myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF
Recovery
19 1996 Switzerland 42 ⁄M Cutaneous Acute myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF
Recovery
20 1996 Switzerland 48 ⁄M Cutaneous Non-Hodgkin Burkitt
lymphoma
AMB, ITZ, FCZ, GSV,
5FC, TBF
Recovery
21 1996 Switzerland 54 ⁄M Cutaneous Myelodysplastic
syndrome
AMB, ITZ, FCZ, GSV, Recovery
22 1996 Switzerland 32 ⁄ F Cutaneous Acute myelogenous
leukaemia
AMB, ITZ, FCZ, GSV,
5FC, TBF
Recovery
23 1996 [70] USA 35 ⁄M Cutaneous,
bursitis
Local corticosteroid
injection
MCZ, KTZ, surgery Recovery
24 1997 [28] USA 56 ⁄M Cutaneous Liver transplant ITZ, AMB, i.v and
topical MCZ
Died
25 1997 USA 86 ⁄M Cutaneous Unknown ITZ Recovery
26 1997 [13] USA NR Cutaneous ⁄
sub-cutaneous
Heart transplant NR Recovery
27 1997 USA NR Cutaneous ⁄
sub-cutaneous
Renal transplant NR Recovery
28 1997 USA NR Cutaneous ⁄
sub-cutaneous
Acute lymphocytic
leukaemia
NR Died
29 1997 USA NR Cutaneous ⁄
sub-cutaneous
Acute myelogenous
leukaemia
NR Died
30 1998 [88] USA 72 ⁄M Sub-cutaneous Corticosteroids ITZ Recovery
31 1999 [3] USA 48 ⁄M Cutaneous ⁄
sub-cutaneous
Heart transplant ITZ, AMB, FCZ
L-AMB, ITZ solution,
TBF
Recovery
32 1999 [4] Spain 36 ⁄M Cutaneous Unknown ITZ Recovery
33 2000 [29] UK 58 ⁄M Cutaneous ⁄
sub-cutaneous
Unknown FCZ, TBF, surgery, GSV,
TBF
Recovery
34 2000 [89] Iceland 59 ⁄M Cutaneous Renal transplant ITZ, VCZ,
immunosuppression
reduction
Recovery
35 2001 [30] Australia 59 ⁄ F Cutaneous Unknown ITZ Recovery
36 2002 [86] USA 40 ⁄M Cutaneous ⁄
sub-cutaneous
AIDS ITZ, AMB, AMB lipid
complex, VCZ
Recovery
37 2002 [34] USA 64 ⁄ F Cutaneous Diabetes mellitus,
metastatic carcinoma
of the pancreas
ITZ, CSP Recovery
38 2003 [35] Germany 43 ⁄M Sub-cutaneous Liver cirrhosis Surgery, AMB Recovery
39 2004 [84] France 84 ⁄M Cutaneous Prednisone therapy Surgery, VCZ Recovery
40 2004 [31] USA 73 ⁄ F Cutaneous Prednisone therapy ITZ Recovery
41 2004 USA 65 ⁄M Cutaneous Unknown ITZ, FCZ, surgery NR
42 2004 USA 63 ⁄M Cutaneous Heart transplant Surgery Died but probably from
other causes
NR, not reported.
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
AMB, amphotericin B; CSP, caspofungin; CTZ, clotrimazole; FCZ, ﬂuconazole; GSV, griseofulvin; ITZ, itraconazole; KCZ, ketoconazole; L-AMB, liposomal amphotericin B;
MCZ, miconazole; TBF, terbinaﬁne; VCZ, voriconazole; 5FC, ﬂucytosine.
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IN-VITRO SUSCEPTIBILITY
Data concerning the in-vitro antifungal suscepti-
bility of P. lilacinus are scarce; some reports do not
refer to a particular species, but to Paecilomyces in
general [51–55]. As antifungal susceptibilities
vary considerably among the different species of
Paecilomyces, the usefulness of such reports is very
limited without species identiﬁcation [56].
Table 4 summarises the available data concern-
ing the in-vitro activity of the various antifungal
drugs against P. lilacinus. The important differ-
ences among the data provided from various
studies can be explained by the different methods
used. The CLSI broth microdilution method for
yeasts (M27-A) [57] was used in some studies
[51,56], while others [52–54,58–61] used the guide-
lines for moulds (M38-P, M38-A) [62,63]. Broth
macrodilution, Etest and colourimetric methods
were used in other studies [54,55,59,64]. With the
exception of amphotericin B, for which all studies
used 100% growth inhibition (MIC-0), important
discrepancies also occurred in the endpoint cri-
teria used. Thus, MIC-0 was often chosen as the
endpoint criterion for all antifungal drugs tested
[53,54,58–61], while other studies used 75% (MIC-
1) or 50% (MIC-2) growth inhibition as the
endpoint [51,52,56,64]. Diekema et al. [53] used
the minimum effective concentration (MEC) as
the endpoint for caspofungin.
Overall, amphotericin B has poor in-vitro activ-
ity against P. lilacinus. MIC values of this drug
were always > 2 mg ⁄L, and usually > 8 mg ⁄L
[18,20,24,56,58–60,65–68]. This absence of activity
of amphotericin B was corroborated by its repor-
ted high minimum fungicidal concentrations
(MFC) [56,58].
As with many other ﬁlamentous fungi, the in-
vitro activity of ﬂucytosine and ﬂuconazole
against P. lilacinus is practically nil, with very
high MICs [3,12,20,48,56,65,69–71] and MFCs [56].
There are contrasting data concerning the activity
of the older azoles, such as ketoconazole,
miconazole, clotrimazole and itraconazole
[3,5,12,18,24,65,70]. As an example, most studies
report itraconazole MICs of > 2 mg ⁄L [56,58–
60,68], while others report considerably lower
MICs of £ 0.01–0.5 mg ⁄L [18,66].
Interestingly, some of the novel antifungal
drugs have shown some degree of in-vitro activity
against P. lilacinus. Among the triazoles, posac-
onazole has the lowest MICs, ranging from 0.12 to
0.5 mg ⁄L [60]. The MICs of voriconazole were
more variable, ranging from 0.12 to 4 mg ⁄L
[57,58,60]. Similar results were obtained with the
new triazole albaconazole (UR-9825), for which
MICs ranged from 0.06 to 0.5 mg ⁄L [67] and from
0.5 to 8 mg ⁄L [57]. Ravuconazole also shows good
in-vitro activity against P. lilacinus, with MICs
ranging from 0.2 to 2 mg ⁄L [57,60]. MICs of
Table 3. Reported cases of non-ocular, non-cutaneous infections caused by Paecilomyces lilacinus
Case Year Reference Country
Age ⁄
gender Infection Predisposing factors Treatment Outcome
1 1972 [39] Malta 20 ⁄M Pleural effusion Unknown AMB Recovery
2 1980 [40] USA 47 ⁄ F Chronic sinusitis Unknown Surgery Recovery
3 1982 [92] USA 47 ⁄ F Sinusitis Previous
nasoantrostomy
Surgery Recovery
4 1992 [46] Spain 7 ⁄M Fungaemia Acute lymphoblastic
leukaemia
AMB Recovery
5 1992 [47] USA 1.5 ⁄M Fungaemia Rhabdomyosarcoma AMB Recovery
6 1996 [41] USA 22 ⁄ F Sinusitis Myeloid leukaemia AMB, 5FC, ITZ Recovery, died of
other causes
7 1996 [13] USA NR Lung,
disseminated
Acute lymphocytic
leukaemia
NR Recovery
8 1997 [42] USA 57 ⁄ F Sinusitis Diabetes mellitus Surgery, AMB plus ITZ Recovery
9 1998 [37] UK 59 ⁄ F Onychomycosis Unknown TBF, topical AMF, nail
ablation
Stable disease in new nail
10 1999 [48] USA 36 ⁄ F Fungaemia Bone marrow transplant AMB, 5FC, GM-CSF Recovery
11 1999 [44] USA 43 ⁄M Osteomyelitis Bone marrow transplant AMB, MCZ, surgery Recovery, died of
other causes
12 1999 [38] Japan 57 ⁄M Lung abscess Unknown Lobectomy Recovery
13 2000 [43] India 8 ⁄M Sinusitis Unknown Surgery, ITZ Recovery
14 2002 [45] USA 61 ⁄M Disseminated AIDS AMB, ITZ Recovery
15 2003 [5] USA 48 ⁄ F Vaginitis Unknown FCZ, topical CTZ, topical
TNZ, boric acid gel, ITZ
Recovery
16 2003 [49] Chile 5 ⁄M Fungaemia Myeloid leukaemia FCZ, AMB plus ITZ Recovery
NR, not reported.
GM-CSF, granulocyte-macrophage colony-stimulating factor.
AMB, amphotericin B; AMF, amorolﬁne; CTZ, clotrimazole; FCZ, ﬂuconazole; ITZ, itraconazole; TNZ, tioconazole; 5FC, ﬂucytosine.
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0.25–0.50 mg ⁄L have been reported for terbina-
ﬁne [61], while other studies have reported MICs
of 1–8 mg ⁄L [57]. Limited and controversial data
exist concerning the in-vitro activity of echino-
candins. For caspofungin, MICs of 3.12 mg ⁄L to
> 100 mg ⁄L (geometric mean of 49.98 mg ⁄L) have
been reported [64], while micafungin MICs of
£ 0.01 mg ⁄L were reported in one study [66],
compared with 64 mg ⁄L in another [57].
Because of the high resistance shown by
P. lilacinus to conventional antifungal drugs, the
potential activity of various in-vitro combinations
has also been tested. In a study involving three
isolates of this fungus, although the interaction
was generally indifferent, amphotericin B MICs of
> 16 mg ⁄L were reduced to 0.12 mg ⁄L when
combined with voriconazole, ravuconazole,
albaconazole or terbinaﬁne [57]. Amphotericin B
combined with terbinaﬁne or albaconazole result-
ed in synergic interactions against two and one
isolate(s), respectively. Combinations of terbina-
ﬁne with voriconazole, itraconazole, ravuconazole
or albaconazole also showed synergism against
some of the isolates tested [57]. However, further
studies are needed to evaluate the possible clin-
ical signiﬁcance of these observations.
ANIMAL MODELS
The virulence of some species of Paecilomyces has
been evaluated in different animal models, e.g.,
mice, guinea-pigs, rats and rabbits, using intra-
peritoneal, sub-cutaneous, intra-testicular, intra-
muscular, intra-corneal and intra-orbital methods
of infection [72–76]. In general, virulence was very
low, requiring high inocula and immunosup-
pression of the animals to produce an estab-
lished infection. Thus, experimental infection of
immunocompetent mice by a strain of P. lilacinus
using an intra-peritoneal route required a period
of 2 months before peritoneal granulomas devel-
oped, and it was not possible to recover viable
Table 4. In-vitro antifungal susceptibilities of Paecilomyces lilacinus
Ref.
No. of
strains
Antifungal drugs (MICs mg ⁄L)
AMB 5FC FLC KCZ MCZ ITZ ABZ VCZ RVZ PSZ TBF MFG CSP
[77] 1a 25 > 50 ) ) 6.25 ) ) ) ) ) ) ) )
[78] 1a > 20 > 200 ) ) 20 ) ) ) ) ) ) ) )
[20] 3a,b 25 > 50 ) 6.25 ) ) ) ) ) ) ) ) )
[94] 2a,c > 32 > 250 ) 0.62–1.25 0.62–10 ) ) ) ) ) ) ) )
[24] 3c > 16 2) > 18 ) < 1–3 0.25–7 ) ) ) ) ) ) ) )
[65] 4c > 4 > 250 ) 0.31–0.62 0.15) > 20 ) ) ) ) ) ) ) )
[70] 1d > 16 ) 64 1 0.5 16 ) ) ) ) ) ) )
[12] NDa 16 ) 64 0.50 0.5–1 4 ) ) ) ) ) ) )
[41] 1 4.62 ) 64 ) ) 0.5 ) ) ) ) ) ) )
[21] 1a > 64 ) ) 16 32 > 64 ) ) ) ) ) ) )
[42] 1a > 16 ) ) ) ) 0.13 ) ) ) ) ) ) )
[64] 5c,d ) ) ) ) ) ) ) ) ) ) ) ) 3.12) > 100
[56] 11b,e 10.29 255.96 116.46 3.52 6.02 7.51 ) ) ) ) ) ) )
[51] 1e,f 4 > 128 ) ) ) 4 ) ) ) ) ) ) 0.5
[3] 1a 2 > 64 > 64 1 ) 4 ) ) ) 0.08 ) )
[48] 1d > 16 > 64 > 64 ) ) 1 ) ) ) ) )
[66] 2c,e > 8 ) ) ) ) 0.01–0.5 ) ) ) ) ) < 0.01 )
[89] 1a > 25 ) ) ) ) > 25 ) 1.56 ) ) ) ) )
[30] 1g > 32 ) > 32 ) ) 0.5 ) ) ) ) ) ) )
[25] 1a 16 128 ) ) ) ) ) ) ) ) ) ) )
[67] 10b,c > 16 ) ) ) ) ) 0.06–0.5 ) ) ) ) ) )
[58] 6c,d > 8 ) ) ) ) 2) > 8 ) 0.12–0.5 ) ) ) ) )
[59] 4c,e,g > 8 ) ) ) ) 2) > 8 ) ) ) ) ) ) )
[86] 1a > 8 ) ) ) ) 2 ) 0.12 ) ) ) ) )
[34] 1a 16 ) ) 1 ) 1 ) 0.25 0.50 0.12 ) ) 1.00
[22] 1a > 16 ) ) ) ) 0.5 ) 0.25 ) ) ) ) )
[52] 2e,f 0.50 ) ) ) ) 0.25–0.5 ) 2–8 1–8 0.12–0.5 ) ) )
[60] 3f,h > 8 ) ) ) ) 1) > 8 ) 0.20–1 0.20–2 0.12–0.5 ) ) )
[53] 6e,f 0.06) > 8 ) ) ) ) 0.06–2 ) 0.03–2 0.03–4 0.03–0.5 ) ) 0.03–8
[35] 1e > 16 ) ) ) ) > 16 ) 2 ) ) 1 > 8 )
[18] 3c,e 2 > 64 8–64 0.25)0.50 ) 0.5 ) 0.12 ) ) ) ) )
[5] 1d > 16 > 64 32 0.5 ) 0.5 ) 0.25 ) 0.12 ) ) )
[55] 1f,h 2 > 64 > 256 > 16 ) > 16 ) 4 ) ) ) ) )
[61] 6c,e ) ) ) ) ) ) ) ) ) ) 0.25–0.5 ) )
[68] 3c,e 16 ) ) ) ) 32 0.5–8 0.25–4 0.25–2 ) 1–8 64 )
AMB, amphotericin B; 5FC, ﬂucytosine; FLC, ﬂuconazole; KCZ, ketoconazole; MCZ, miconazole; ITZ, itraconazole; ABZ, albaconazole; VCZ, voriconazole; RVZ, ravuconazole;
PSZ, posaconazole; TBF, terbinaﬁne; MFG, micafungin; CSP, caspofungin.
ND, number of strains not speciﬁed.
aSusceptibility method not reported; bgeometric mean MICs; cMIC range; dmacrodilution broth method; emicrodilution broth method; freferred as Paecilomyces spp.; gEtest;
halamar blue.
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fungi from the granulomas [73]. Agrawal et al.
[72] reported a greater effect in animals treated
with hydrocortisone acetate than in immunocom-
petent animals in a model of corneal infection in
rabbits. More recently, an experimental murine
model of disseminated infection using mice im-
munosuppressed with cyclophosphamide was
used to compare the pathogenicity of P. variotii,
P. lilacinus and P. javanicus, and demonstrated a
higher virulence for strains belonging to the ﬁrst
two of these species [74]. With the development of
these models, studies of pathogenesis, host
response and therapy of paecilomycosis have
become possible. The murine model has been
used to evaluate the efﬁcacy of amphotericin B
deoxycholate and its liposomal formulation
against disseminated infection caused by P. var-
iotii, and demonstrated the usefulness of both
compounds and the higher activity of the lipo-
somal amphotericin B in the treatment of this
experimental infection [75].
TREATMENT AND OUTCOME
The optimal treatment for P. lilacinus infections
has not yet been established. In localised infec-
tions, removal of the infected foci and elimination
of any foreign body should be attempted if
feasible [1].
Ocular infections
No standard treatment exists for ocular infections
caused by P. lilacinus. Outcomes of the various
treatments used to date range from eye enuclea-
tion to total recovery (Table 1). Favourable out-
comes were obtained in only 17 (28.3%) of the 60
cases described in the literature. Eye enucleation
was required in 20 (33.3%) cases, which demon-
strates the potentially devastating effects of this
fungus for ocular structures. Other treatment
regimens used one or several drugs administered
by a topical, sub-conjunctival and ⁄ or intra-ocular
route, sometimes combined with systemic treat-
ment, and associated commonly with surgical
procedures, e.g., keratoplasty, total or partial
vitrectomy, removal of the intra-ocular lens or
corneal transplant.
In general, in-vitro susceptibility of clinical
isolates to amphotericin B and ﬂucytosine is very
low [18,20,21,24,25,77,78], which corresponds
with observations that use of systemic amphoter-
icin B alone was ineffective, with infection being
resolved in only one (6.2%) of 16 cases in which
this approach was used [15]. Local administration
of amphotericin B resulted in similarly poor
outcomes, with recovery in only three of 19 cases.
In two of these three cases of recovery, success
was achieved only after surgery [79,80], and in the
other it was achieved following intra-ocular
administration of amphotericin B and ﬂuconazole
[17]. The use of both systemic and local admin-
istration of amphotericin B did not improve
outcome, with recovery achieved in only two of
seven patients treated with this regimen [14,81].
Miconazole was used in nine cases
[14,21,24,65,78,80,82], but resolved only two
[24,65]; in one of these it was used topically [24],
and in the other it was administered systemically,
followed by surgery [65]. Systemic and local
administration of ﬂucytosine has also been used
unsuccessfully, with improvement in only one
(4.7%) of 21 cases; the one success was in
combination with amphotericin B, but the aetiol-
ogy of P. lilacinus could not be conﬁrmed [20].
Fluconazole was administered to seven patients,
only two of whom were cured; in one of the two
favourable cases, ﬂuconazole was used in combi-
nation with amphotericin B [17], and in the other
ﬂuconazole was administered intra-vitreally fol-
lowed by surgical treatment [80]. Although vor-
iconazole has been used in only ﬁve documented
cases, this drug demonstrated a high level of
efﬁcacy, resolving four cases [18,19,22], in one of
which voriconazole was combined with terbina-
ﬁne [19].
Cutaneous and sub-cutaneous infections
The treatments and outcomes of the reported
cases of cutaneous and sub-cutaneous infections
caused by P. lilacinus are summarised in Table 2.
In two cases, surgical debridement was sufﬁcient
to cure the infection [31,83]. In another case,
infection persisted with recurrences, but no dis-
semination occurred after surgical debridements,
which were repeated for a period of 2.5 years [9].
In six cases, surgical treatment was carried out
either in association with antifungal drug therapy
or following other surgery [9,31,35,70,84], curing
the infection in all except one case, for which the
outcome was unknown [31]. In 30 cases, therapy
comprised antifungal drugs, e.g., amphotericin B,
ﬂucytosine, miconazole, ﬂuconazole, ketoconaz-
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ole, itraconazole, voriconazole, caspofungin and
terbinaﬁne, alone or in combinations. Successful
outcomes were obtained in 22 (73.3%) cases,
generally after the sequential administration of
several antifungal drugs after failure of the
drug(s) employed initially. On some occasions
when antifungal treatment had failed, recovery
was possible following correction of neutropenia
[12].
Amphotericin B, alone or associated with sur-
gery, was used in 17 cases, but was unsuccessful
in 15 (88.2%) cases [3,12,28,33,36,85,86]. One of
the two successful cases involved a child with
chronic granulomatous disease, who was cured
with amphotericin B [87], and the other was a
cirrhotic male, who was cured with amphotericin
B and surgical debridement [35]. In the latter case,
the strain showed in-vitro resistance to ampho-
tericin B (MIC > 16 mg ⁄L). In general, MICs of
> 2 mg ⁄L were observed in those cases with
unsuccessful outcomes for which the causative
strain had been tested in vitro [3,12,86].
Itraconazole has been used to treat 20 patients
[3,4,12,28,30,31,34,86,88,89], but a successful out-
come was obtained in only four cases
[4,30,31,88]. A relationship between in-vitro
resistance of the clinical isolates to itraconazole
and treatment failure was observed in two cases
[3,89], but this correlation was not always found.
For example, the strain in the case reported by
Gottlieb et al. [30], which resolved, had an
itraconazole MIC of 0.5 mg ⁄L, but no clinical
response was obtained with itraconazole in
another case in which the isolate had similar
in-vitro susceptibility [31]. A favourable outcome
was obtained with itraconazole plus caspofungin
in a cutaneous infection that failed to resolve
with itraconazole alone. In this case the clinical
isolate had MICs of 1–4 mg ⁄L [34]. However, in
most of the cases resolved with itraconazole, no
data on in-vitro susceptibility were available
[4,31,88].
Despite their known poor activity against
P. lilacinus, ﬂucytosine and ﬂuconazole have also
been used in the treatment of cutaneous and
sub-cutaneous infections caused by this fungus,
but usually with a negative outcome. Only one of
11 cases treated with ﬂucytosine was resolved
when this drug was added to a previous amph-
otericin B treatment that had failed [33]. Similarly,
failure was the outcome in 12 cases treated with
ﬂuconazole.
In contrast, favourable outcomes were ob-
tained in the few cases in which voriconazole
was administered. This drug resolved the infec-
tion in four cases [34,84,86,89], although the
MIC for the clinical isolate was relatively high
(1.56 mg ⁄L) [89] in one case. The MICs for
isolates in another three cases were considerably
lower [34,84,86]. Ketoconazole has also been
used successfully in four cases of cutaneous and
sub-cutaneous infection [27,70,90,91]; in one case
it was combined with surgery [70]. No data
have been published concerning the clinical use
of posaconazole or ravuconazole. Therapy with
terbinaﬁne failed in the treatment of an
outbreak that included nine patients with cuta-
neous and sub-cutaneous infection [12,32]. How-
ever, terbinaﬁne was effective in one case for
which the isolate showed in-vitro susceptibility
[3], and in another case when used in combi-
nation with griseofulvin [29].
Non-ocular, non-cutaneous infections
In contrast to the infections mentioned above, in
which the rate of successful treatment was very
low, all described cases of non-cutaneous, non-
ocular infections caused by P. lilacinus have been
resolved with antifungal and ⁄ or surgical treat-
ment (Table 3). Surgery was effective as sole
treatment in three cases [38,40,92], and when
combined with itraconazole in one case [43]. One
case of osteomyelitis was resolved by surgery
after the failure of initial treatment with ampho-
tericin B and miconazole [44]. Itraconazole was
used in ﬁve (31.2%) of the 16 reported cases of
non-cutaneous, non-ocular infections by P. lilaci-
nus, with a favourable outcome in all cases [5,41–
43,49]. When tested, the in-vitro susceptibility of
clinical isolates to itraconazole was high, which
correlated with the positive clinical outcomes
[5,41,42,45]. Amphotericin B resolved the seven
cases in which this drug was used. Despite the
high MICs of amphotericin B for the isolates from
two [46,48] of the four reported cases of fungae-
mia, recovery was obtained in all four cases [46–
49]. In one of these cases, amphotericin B was
combined with ﬂucytosine and granulocyte-macr-
ophage colony-stimulating factor [48], and in
another with itraconazole [49]. In two of these
four cases of fungaemia, medical treatment was
combined with the removal of a central venous
catheter [46,47].
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CONCLUSIONS
P. lilacinus is an emerging pathogenic mould that
is able to cause severe cutaneous and sub-cuta-
neous infections and devastating oculomycosis.
Less frequently, this fungus is reported as a
causative agent of infections in other body loca-
tions. Although P. lilacinus infections have been
described in previously healthy individuals, the
majority of cases described in the literature
involve patients with identiﬁed predisposing
factors. In cases of oculomycosis, intra-ocular lens
implantation and non-surgical trauma were the
most frequent predisposing factors, followed by
ocular surgery. Generally, oculomycosis patients
had received topical or systemic corticosteroid
therapy. The most common predisposing factors
for cutaneous and sub-cutaneous infections were
solid organ and bone marrow transplants, malig-
nancy and corticosteroid therapy. Fungaemia was
related to the use of central venous catheters.
In contrast to the other species belonging to the
genus, P. lilacinus generally shows a poor re-
sponse to conventional antifungal drugs. There-
fore, correct identiﬁcation of clinical isolates to the
species level is mandatory for appropriate treat-
ment of the disease. Many therapeutic regimens
have been used to treat paecilomycosis, but with a
high failure rate. Recovery of neutropenia and
removal of central venous catheters, if present, are
essential to resolve the infection. In many cases,
surgery must be combined with medical treat-
ment. The older antifungal drugs, such as amph-
otericin B, ﬂucytosine, ﬂuconazole, miconazole
and itraconazole have been used in many cases of
cutaneous, sub-cutaneous and ocular infections,
but generally with unfavourable outcomes.
Although there is limited clinical experience in
the use of voriconazole, this drug seems to be the
most effective agent for the treatment of these
fungal infections. Posaconazole and ravuconazole
may be good alternatives on the basis of their
excellent activity in vitro.
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